Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
Bimodal effects of the Kv7 channel activator retigabine on vascular K+ currents.
Yeung S
,
Schwake M
,
Pucovský V
,
Greenwood Ia
.
???displayArticle.abstract???
BACKGROUND AND PURPOSE: This study investigated the functional and electrophysiological effects of the Kv7 channel activator, retigabine, on murine portal vein smooth muscle.
EXPERIMENTAL APPROACH: KCNQ gene expression was determined by reverse transcriptase polymerase chain reaction (RT-PCR) and immunocytochemical experiments. Whole cell voltage clamp and current clamp were performed on isolated myocytes from murine portal vein. Isometric tension recordings were performed on whole portal veins. K+ currents generated by KCNQ4 and KCNQ5 expression were recorded by two-electrode voltage clamp in Xenopus oocytes.
KEY RESULTS: KCNQ1, 4 and 5 were expressed in mRNA derived from murine portal vein, either as whole tissue or isolated myocytes. Kv7.1 and Kv7.4 proteins were identified in the cell membranes of myocytes by immunocytochemistry. Retigabine (2-20 microM) suppressed spontaneous contractions in whole portal veins, hyperpolarized the membrane potential and augmented potassium currents at -20 mV. At more depolarized potentials, retigabine and flupirtine, decreased potassium currents. Both effects of retigabine were prevented by prior application of the K(v)7 blocker XE991 (10 muM). Recombinant KCNQ 4 or 5 channels were only activated by retigabine or flupirtine.
CONCLUSIONS AND IMPLICATIONS: The Kv7 channel activators retigabine and flupirtine have bimodal effects on vascular potassium currents, which are not seen with recombinant KCNQ channels. These results provide support for KCNQ4- or KCNQ5-encoded channels having an important functional impact in the vasculature.
Alexander,
Guide to Receptors and Channels (GRAC), 3rd edition.
2008, Pubmed
Alexander,
Guide to Receptors and Channels (GRAC), 3rd edition.
2008,
Pubmed
Brueggemann,
Vasopressin stimulates action potential firing by protein kinase C-dependent inhibition of KCNQ5 in A7r5 rat aortic smooth muscle cells.
2007,
Pubmed
Dupuis,
Activation of KCNQ5 channels stably expressed in HEK293 cells by BMS-204352.
2002,
Pubmed
Grunnet,
KCNE4 is an inhibitory subunit to the KCNQ1 channel.
2002,
Pubmed
,
Xenbase
Jentsch,
Neuronal KCNQ potassium channels: physiology and role in disease.
2000,
Pubmed
Joshi,
Pulmonary vasoconstrictor action of KCNQ potassium channel blockers.
2006,
Pubmed
Kharkovets,
KCNQ4, a K+ channel mutated in a form of dominant deafness, is expressed in the inner ear and the central auditory pathway.
2000,
Pubmed
Kubisch,
KCNQ4, a novel potassium channel expressed in sensory outer hair cells, is mutated in dominant deafness.
1999,
Pubmed
,
Xenbase
Lerche,
Chromanol 293B binding in KCNQ1 (Kv7.1) channels involves electrostatic interactions with a potassium ion in the selectivity filter.
2007,
Pubmed
,
Xenbase
Main,
Modulation of KCNQ2/3 potassium channels by the novel anticonvulsant retigabine.
2000,
Pubmed
,
Xenbase
Ohya,
Molecular and functional characterization of ERG, KCNQ, and KCNE subtypes in rat stomach smooth muscle.
2002,
Pubmed
Ohya,
Functional and molecular identification of ERG channels in murine portal vein myocytes.
2002,
Pubmed
Ohya,
Molecular variants of KCNQ channels expressed in murine portal vein myocytes: a role in delayed rectifier current.
2003,
Pubmed
Porter,
Retigabine.
2007,
Pubmed
Rundfeldt,
The new anticonvulsant retigabine (D-23129) acts as an opener of K+ channels in neuronal cells.
1997,
Pubmed
Saleh,
Electrophysiological and molecular identification of voltage-gated sodium channels in murine vascular myocytes.
2005,
Pubmed
Schenzer,
Molecular determinants of KCNQ (Kv7) K+ channel sensitivity to the anticonvulsant retigabine.
2005,
Pubmed
,
Xenbase
Schroeder,
KCNQ5, a novel potassium channel broadly expressed in brain, mediates M-type currents.
2000,
Pubmed
Strutz-Seebohm,
Functional coassembly of KCNQ4 with KCNE-beta- subunits in Xenopus oocytes.
2006,
Pubmed
,
Xenbase
Tatulian,
Activation of expressed KCNQ potassium currents and native neuronal M-type potassium currents by the anti-convulsant drug retigabine.
2001,
Pubmed
Wang,
KCNQ2 and KCNQ3 potassium channel subunits: molecular correlates of the M-channel.
1998,
Pubmed
,
Xenbase
Wang,
Molecular basis for differential sensitivity of KCNQ and I(Ks) channels to the cognitive enhancer XE991.
2000,
Pubmed
,
Xenbase
Wickenden,
Retigabine, a novel anti-convulsant, enhances activation of KCNQ2/Q3 potassium channels.
2000,
Pubmed
Wickenden,
Characterization of KCNQ5/Q3 potassium channels expressed in mammalian cells.
2001,
Pubmed
,
Xenbase
Wladyka,
KCNQ/M-currents contribute to the resting membrane potential in rat visceral sensory neurons.
2006,
Pubmed
Wuttke,
The new anticonvulsant retigabine favors voltage-dependent opening of the Kv7.2 (KCNQ2) channel by binding to its activation gate.
2005,
Pubmed
,
Xenbase
Yeung,
Electrophysiological and functional effects of the KCNQ channel blocker XE991 on murine portal vein smooth muscle cells.
2005,
Pubmed
Yeung,
Molecular expression and pharmacological identification of a role for K(v)7 channels in murine vascular reactivity.
2007,
Pubmed
